673 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib http://www.zacks.com/stock/news/679808/gilead-gild-files-nda-with-fda-for-ra-candidate-filgotinib?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-679808 Dec 20, 2019 - Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland http://www.zacks.com/stock/news/678361/the-zacks-analyst-blog-highlights-johnson-johnson-eli-lilly-pnc-financial-eog-resources-and-archer-daniels-midland?cid=CS-ZC-FT-press_releases-678361 Dec 19, 2019 - The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland
Pfizer's Braftovi sNDA Accepted by FDA for Priority Review http://www.zacks.com/stock/news/678304/pfizers-braftovi-snda-accepted-by-fda-for-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-678304 Dec 19, 2019 - FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial http://www.zacks.com/research-daily/676738/top-stock-reports-for-johnson-johnson-eli-lilly-pnc-financial?cid=CS-ZC-FT-research_daily-676738 Dec 18, 2019 - Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial
Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020 http://www.zacks.com/stock/news/676513/lillys-stock-up-on-upbeat-sales-profit-outlook-for-2020?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-676513 Dec 18, 2019 - Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Story Stocks: Eli Lilly's new product growth has pharmaceutical company feeling revived (LLY) https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=NS20191217082045StoryStocks Dec 17, 2019 - Over the past couple of years, patents have expired on a few of Eli Lilly's (LLY) key drugs, most no
Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC http://www.zacks.com/stock/news/673027/lillys-cyramza-gets-chmp-recommendation-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-673027 Dec 16, 2019 - Lilly's (LLY) regulatory application seeking approval for cancer drug, Cyramza, in combination with erlotinib for treating EGFR-mutated NSCLC in first-line setting gets positive CHMP opinion for approval in EU.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study http://www.zacks.com/stock/news/668756/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|stock_roundup-668756 Dec 13, 2019 - This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor http://www.zacks.com/stock/news/667111/lilly-initiates-phase-iii-lung-cancer-study-on-ret-inhibitor?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-667111 Dec 12, 2019 - Lilly (LLY) initiates a phase III study on its oral RET inhibitor, selpercatinib, in treatment-naive, RET fusion-positive NSCLC patients.
3 Biotech Stocks With a Lot to Prove at ASH 2019 https://www.fool.com/investing/2019/12/02/3-biotech-stocks-with-a-lot-to-prove-at-ash-2019.aspx?source=iedfolrf0000001 Dec 02, 2019 - These companies have some important presentations scheduled for the last big oncology conference of the year.

Pages: 12345678...68

<<<Page 3>